“Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a study led by the University of California, San Francisco (UCSF) showing a broad distribution of Oncotype DX® Genomic Prostate Score (GPS) results among prostate MRI findings, suggesting that these two technologies may provide non-overlapping clinical information in men with localized prostate cancer.
” ‘For the first time, we looked at the association between information provided by a genomic assay and a prostate MRI to better understand the value these two technologies bring to clinical practice,’ said Michael Leapman, M.D., lead investigator from UCSF. ‘These new data show that, in some patients, further risk stratification may be possible, and tools such as GPS may add important biological information to more precisely assess the aggressiveness of a patient’s cancer.’
“In this study, researchers conducted a retrospective evaluation of the statistical association between the Oncotype DX GPS results and contributing gene groups with baseline endorectal MRI in 100 patients with clinically localized prostate cancer. The results showed a large variation of GPS results across MRI findings, demonstrating that Oncotype DX and MRI offer non-overlapping clinical insights in patients with early-stage prostate cancer.”
Standard risk criteria says that between 5% and 10% of men with prostate cancer should receive active surveillance in place of immediate aggressive therapy. However, a new gene test that accounts for biological response, androgen signaling, and tumor growth and proliferation more than doubled that figure. Researchers found that patient data from the Gene Prostate Score (GPS), a 17-gene test, combined with the standard criteria yielded results indicating that 25% of men with prostate cancer would be eligible for active surveillance. The GPS is scored on a 100-point scale, and researchers found that each 20-point increase in a patient’s score was associated with a doubling of the risk for adverse pathology. A study involving 395 patients found that nearly half of the participants had at least a 5% shift in risk when evaluated just by standard criteria and then reevaluated by the GPS in conjunction with standard criteria. Researchers say the GPS should increase the number of men confidently able to choose active surveillance as their initial treatment strategy.